- Home
- OGN
OGN
Organon & Co.
as 11-21-2024 11:37am EST
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
| Founded: | 1923 | Country: | United States |
| Employees: | N/A | City: | JERSEY CITY |
| Market Cap: | 4.7B | IPO Year: | N/A |
| Target Price: | $21.33 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 5.04 | EPS Growth: | 120.97 |
| 52 Week Low/High: | $10.84 - $23.10 | Next Earning Date: | 10-31-2024 |
| Revenue: | $6,409,000,000 | Revenue Growth: | 4.21% |
| Revenue Growth (this year): | 3.13% | Revenue Growth (next year): | 2.18% |
Latest Organon & Co. News
OGN Breaking Stock News: Dive into OGN Ticker-Specific Updates for Smart Investing
Argus Research
9 days ago
OGN: Rating decreased to a HOLD
Simply Wall St.
13 days ago
Organon's (NYSE:OGN) Earnings Are Weaker Than They Seem
Argus Research
16 days ago
OGN: Lowering target price to $18.00
Simply Wall St.
16 days ago
Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Business Wire
16 days ago
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
Simply Wall St.
18 days ago
Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28
Simply Wall St.
20 days ago
Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023)
Business Wire
21 days ago
Organon Reports Results for the Third Quarter Ended September 30, 2024
Compare OGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OGN Organon & Co. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.